Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eagle Pharmaceuticals Inc.

www.eagleus.com

Latest From Eagle Pharmaceuticals Inc.

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date

Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.

StartUps and SMEs Financing

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.

Complete Response Letters Regulation

Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eagle Pharmaceuticals Inc.
  • Senior Management
  • Scott L Tarriff, CEO
    Peter Meyers, CFO
    Steven L Krill, PhD, EVP, CSO
    Adrian Hepner, MD, PhD, EVP, CMO
    David Pernock, Pres. & Chief Commercial Officer
  • Contact Info
  • Eagle Pharmaceuticals Inc.
    Phone: (201) 326-5300
    50 Tice Blvd.
    Ste. 315
    Woodcliff Lake, NJ 07677
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register